Olema Pharmaceuticals, Inc. (OLMA): Total Liabilities
$54.87M
As of 2025-12-31
$56.01M
As of 2026-06-30
+44.7%
3-year compound annual growth
+64.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $54.87M | +30.6% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $42.02M | +82.3% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $23.05M | +27.4% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $18.10M | +59.1% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $11.38M | +148.1% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $4.58M | n/a | 2022-02-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $54.87M | +30.6% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $37.52M | +74.3% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $465.08M | +6.5% |
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | $30.35M | +9.9% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $122.11M | -24.0% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $27.78M | +192.2% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $334.65M | +27.5% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $143.46M | +2.0% |
| Geron Corp (GERN) | 2025-12-31 | $344.67M | +10.0% |
Compare OLMA, DNTH, SNDX, EWTX side by side · Screen every company in Pharmaceutical Preparations ↗